Identification of spastic muscles involved in abnormal joint posture in patients with upper motor neuron syndrome: a narrative review
DOI:
https://doi.org/10.2340/jrm.v58.45077Keywords:
spasticity, botulinum toxin, upper motor neuron syndrome, abnormal joint posture, motor nerve blocks, dynamic EMG, functional anatomyAbstract
Few studies have specifically investigated which muscles are involved in abnormal joint posture (AJP) due to muscle spasticity and should therefore be targeted for botulinum toxin injections. This gap has significant implications for treatment efficiency, safety, health economics, and sustainable healthcare. A 2000 to 2025 (July) PubMed search identified 3,488 articles, but only 7 articles met the criteria for providing a method to determine the muscles involved in AJP due to muscle spasticity. Of these, just 2 have proposed how to measure each muscle contribution and only 1 focused on identifying the muscle actually responsible for the observed AJP. There are many strategies for determining the muscles involved in spasticity-related AJP, but they are primarily based on inference. They draw on clinical skills, which incorporate descriptive and functional anatomy, knowledge of different muscle and joint structures, simple rules of biomechanics, determination of the exact phase of the movement involved, consideration of compensatory AJP in these motor control deficient patterns, and, of course, the patient’s goals. Achieving the authors’ proposed objective would enable the standardization of clinical practices, confirm the effectiveness of treatments for spasticity, particularly botulinum toxin, and ensure that the correct dose is injected in the right muscle.
Downloads
References
Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002; 347: 395–400.
Eapen BC, Tran J, Ballard-Hernandez J, Buelt A, Hoppes CW, Matthews C, et al. Stroke rehabilitation: synopsis of the 2024 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines. Ann Intern Med 2025; 178: 249–268.
Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol 2015; 14: 992–1001.
Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, et al. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: randomized trial and extension. Neurology 2017; 89: 2245–2253.
Esquenazi A, Zorowitz RD, Ashford S, Beneteau M, Maisonobe P, Hannes C, et al. Longitudinal goal attainment with repeat injections of abobotulinumtoxinA in adults with lower limb spasticity: results from a prospective observational study. Arch Phys Med Rehabil 2025; 106: 894–901.
Dong Y, Wu T, Hu X, Wang T. Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis. Eur J Phys Rehabil Med 2017; 53: 256–267.
Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, et al. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol Assess Winch Engl 2010; 14: 1–113.
Santamato A, Micello MF, Panza F, Fortunato F, Pilotto A, Giustini A, et al. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study. Eur J Phys Rehabil Med 2013; 49: 483–489.
Turner-Stokes L, Jacinto J, Fheodoroff K, Brashear A, Maisonobe P, Lysandropoulos A, et al. Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study. J Rehabil Med 2021; 53: 1–11.
Turner-Stokes L, Jacinto J, Fheodoroff K, Brashear A, Maisonobe P, Lysandropoulos A, et al. Assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: first cycle results from the ULIS-III Study. J Rehabil Med 2021; 53: 1–9.
Kwakkel G, Meskers CGM. Botulinum toxin A for upper limb spasticity. Lancet Neurol 2015; 14: 969–971.
Baguley IJ, Nott MT, Turner-Stokes L, De Graaff S, Katrak P, McCrory P, et al. Investigating muscle selection for botulinum toxin-A injections in adults with post-stroke upper limb spasticity. J Rehabil Med 2011; 43: 1032–1037.
Genet F, Schnitzler A, Droz-Bartholet F, Salga M, Tatu L, Debaud C, et al. Successive motor nerve blocks to identify the muscles causing a spasticity pattern: example of the arm flexion pattern. J Anat 2017; 230: 106–116.
Li S. Ankle and foot spasticity patterns in chronic stroke survivors with abnormal gait. Toxins 2020; 12: 1–9.
Li S. Patterns and assessment of spastic hemiplegic gait. Muscle Nerve 2024; 69: 516–522.
Mayer NH. Choosing upper limb muscles for focal intervention after traumatic brain injury. J Head Trauma Rehabil 2004; 19: 119–142.
Esquenazi A. Evaluation and management of spastic gait in patients with traumatic brain injury. J Head Trauma Rehabil 2004; 19: 109–118.
Jacinto J, Camões-Barbosa A, Carda S, Hoad D, Wissel J. A practical guide to botulinum neurotoxin treatment of shoulder spasticity 1: Anatomy, physiology, and goal setting. Front Neurol 2022; 13: 1–9.
Filippetti M, Tamburin S, Di Censo R, Aldegheri R, Mantovani E, Spina S, et al. Do diagnostic nerve blocks affect the starting dose of botulinum neurotoxin type a for spasticity? A case-control study. Toxins 2024; 16: 1–10.
Picelli A, DI Censo R, Angeli C, Spina S, Santamato A, Baricich A, et al. Is the Silfverskiöld Test a valid tool for evaluating calf muscles spastic overactivity in patients with stroke? A retrospective observational study. Eur J Phys Rehabil Med 2024; 60: 761–766.
Jacinto J, Balbert A, Bensmail D, Carda S, Draulans N, Deltombe T, et al. Selecting goals and target muscles for botulinum toxin A injection using the Goal Oriented Facilitated Approach to Spasticity Treatment (GO-FAST) Tool. Toxins 2023; 15: 1–15.
Wieten S. Expertise in evidence-based medicine: a tale of three models. Philos Ethics Humanit Med 2018; 13: 2.
Canevelli M, Jackson-Tarlton C, Rockwood K. Frailty for neurologists: perspectives on how frailty influences care planning. Lancet Neurol 2024; 23: 1147–1157.
Zorowitz RD, Jacinto J, Ashford S, Beneteau M, Maisonobe P, Hannes C, et al. Muscle selection and dosing in patients undergoing treatment with abobotulinumtoxinA for lower limb spasticity in real-world practice. J Rehabil Med 2025; 57: 1–7.
Bakheit AM, Zakine B, Maisonobe P, Aymard C, Fhedoroff K, Hefter H, et al. The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey. Int J Rehabil Res Int Z Rehabil Rev Int Rech Readaptation 2010; 33: 199–204.
Turner-Stokes L, Fheodoroff K, Jacinto J, Maisonobe P. Results from the Upper Limb International Spasticity Study-II (ULIS-II): a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management. BMJ Open 2013; 3: 1–11.
Nott MT, Barden HLH, Baguley IJ. Goal attainment following upper-limb botulinum toxin-A injections: are we facilitating achievement of client-centred goals? J Rehabil Med 2014; 46: 864–868.
Demetrios M, Khan F, Turner-Stokes L, Brand C, McSweeney S. Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post-stroke spasticity. Cochrane Database Syst Rev 2013; 2013: 1–34.
Carpentier VT, Weiss N, Salem JE, Joussain C, Levy J, Mariani LL, et al. Real-life prognosis of neurological complications of botulinum toxin: a nationwide pharmacovigilance study of adverse drug reactions reported in France between 1994 and 2020. Ann Phys Rehabil Med 2025; 68: 1–9.
Esquenazi A, Lee S, Mayer N, Garreta R, Patel A, Elovic E, et al. Patient Registry of Spasticity Care World: data analysis based on physician experience. Am J Phys Med Rehabil 2017; 96: 881–888.
Turner-Stokes L, Fheodoroff K, Jacinto J, Lambert J, De La Loge C, Calvi-Gries F, et al. The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity, Part II: A first psychometric evaluation. J Rehabil Med 2022; 54: 1–9.
Turner-Stokes L, Fheodoroff K, Jacinto J, Lambert J, De La Loge C, Calvi-Gries F, et al. The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity, Part I: Development and responsiveness. J Rehabil Med 2022; 54: 1–9.
Baude M, Nielsen JB, Gracies JM. The neurophysiology of deforming spastic paresis: a revised taxonomy. Ann Phys Rehabil Med 2019; 62: 426–430.
Gracies JM. Pathophysiology of spastic paresis, II: Emergence of muscle overactivity. Muscle Nerve 2005; 3: 552–571.
Deltombe T, Wautier D, De Cloedt P, Fostier M, Gustin T. Assessment and treatment of spastic equinovarus foot after stroke: guidance from the Mont-Godinne interdisciplinary group. J Rehabil Med 2017; 49: 461–468.
Salga M, Gatin L, Deltombe T, Gustin T, Carda S, Marque P, et al. International recommendations to manage poststroke equinovarus foot deformity validated by a panel of experts using delphi. Arch Phys Med Rehabil 2023; 104: 372–379.
Genêt F, Denormandie P, Keenan MA. Orthopaedic surgery for patients with central nervous system lesions: concepts and techniques. Ann Phys Rehabil Med 2019; 62: 225–233.
Yelnik AP, Hentzen C, Cuvillon P, Allart E, Bonan IV, Boyer FC, et al. French clinical guidelines for peripheral motor nerve blocks in a PRM setting. Ann Phys Rehabil Med 2019; 62: 252–264.
Escamilla RF, Fleisig GS, Zheng N, Barrentine SW, Wilk KE, Andrews JR. Biomechanics of the knee during closed kinetic chain and open kinetic chain exercises. Med Sci Sports Exerc 1998; 30: 556–569.
Armand S, Sawacha Z, Goudriaan M, Horsak B, van der Krogt M, Huenaerts C, et al. Current practices in clinical gait analysis in Europe: a comprehensive survey-based study from the European Society for Movement Analysis in Adults and Children (ESMAC) standard initiative. Gait Posture 2024; 111: 65–74.
Roche N, Bonnyaud C, Reynaud V, Bensmail D, Pradon D, Esquenazi A. Motion analysis for the evaluation of muscle overactivity: a point of view. Ann Phys Rehabil Med 2019; 62: 442–452.
Watson F, Fino PC, Thornton M, Heracleous C, Loureiro R, Leong JJH. Use of the margin of stability to quantify stability in pathologic gait: a qualitative systematic review. BMC Musculoskelet Disord 2021; 22: 1–29.
Baker R, Esquenazi A, Benedetti MG, Desloovere K. Gait analysis: clinical facts. J Phys Rehabil Med 2016; 52: 560–574.
Son J, Rymer WZ. Contribution of stroke-related changes in neuromuscular factors to gear ratio during isometric contraction of medial gastrocnemius muscle: a simulation study. Clin Biomech Bristol Avon 2022; 99: 1–9.
Mayer N, Esquenazi A, Keenan MA. Assessing and treating muscle overactivity in the upper motor neuron syndrome. In: Zasler N, Katz D, Zafonte R. Brain injury medicine principles and practice. New York: DEMOS; 2006. P. 615–653.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Francois Genêt, Vincent Carpentier, Guillaume Chambinaud, Alberto Esquenazzi, Marjorie Salga
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.
